Activating KIRs in chronic lymphoproliferative disorder of NK cells: Protection from viruses and disease induction?

Frontiers in Immunology

Volumn 5, Issue FEB, 2014, Pages

  Zambello, Renato ^a,b   Teramo, Antonella ^a,b   Barilà, Gregorio ^a,b   Gattazzo, Cristina ^a,b   Semenzato, Gianpietro ^a,b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Activating KIRs; CLPD NK; NK cell licensing; Pathogenesis in NK disorders; Viral infections

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 5; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

CELL PROLIFERATION; DENDRITIC CELL; EPIGENETICS; GENE EXPRESSION; HUMAN; LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SHORT SURVEY; VIRUS INFECTION;

EID: 84897740904     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00072     Document Type: Short Survey

References (46)

1. Villamor NMWG, Chan WC, Foucar K. Chronic lymphoproliferative disorders of NK cells. In: Swerdlow SH, Campo E, Harris NL, Jaffe EJ, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC (2008). p. 274-5.
2. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood (1993) 82(1):1-14.
3. Semenzato G, Pandolfi F, Chisesi T, De Rossi G, Pizzolo G, Zambello R, et al. The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer (1987) 60(12):2971-8. doi:10.1002/1097-0142(19871215)60:12<::AID-CNCR2820601220>3.0.CO;2-O.
4. Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood (1994) 84(8):2721-5.
5. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood (1997) 89(1):256-60.
6. Oshimi K. Lymphoproliferative disorders of natural killer cells. Int J Hematol (1996) 63(4):279-90. doi:10.1016/0925-5710(96)00450-1.
7. Pandolfi F, Loughran TP Jr, Starkebaum G, Chisesi T, Barbui T, Chan WC, et al. Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer (1990) 65(2):341-8.
8. Zambello R, Semenzato G. Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes. Semin Hematol (2003) 40(3):201-12. doi:10.1016/S0037-1963(03)00134-3.
9. Zambello R, Semenzato G. Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica (2009) 94(10):1341-5. doi:10.3324/haematol.2009.012161.
10. Zambello R, Falco M, Della Chiesa M, Trentin L, Carollo D, Castriconi R, et al. Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood (2003) 102(5):1797-805. doi:10.1182/blood-2002-12-3898.
11. Kawa-Ha K, Ishihara S, Ninomiya T, Yumura-Yagi K, Hara J, Murayama F, et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest (1989) 84(1):51-5. doi:10.1172/JCI114168.
12. Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica (2009) 94(1):135-9. doi:10.3324/haematol.13151.
13. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia (2009) 23(8):1398-405. doi:10.1038/leu.2009.46.
14. Semenzato G, Marino F, Zambello R. State of the art in natural killer cell malignancies. Int J Lab Hematol (2012) 34(2):117-28. doi:10.1111/j.1751-553X.2011.01374.x.
15. Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood (2011) 117(10):2764-74. doi:10.1182/blood-2010-07-296962.
16. Loughran TP Jr, Hadlock KG, Yang Q, Perzova R, Zambello R, Semenzato G, et al. Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3-(natural killer) lymphoproliferative disease of granular lymphocytes. Blood (1997) 90(5):1977-81.
17. Zambello R, Berno T, Cannas G, Baesso I, Binotto G, Bonoldi E, et al. Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL). Blood (2005) 106(12):3926-31. doi:10.1182/blood-2005-05-1972.
18. Hodge DL, Yang J, Buschman MD, Schaughency PM, Dang H, Bere W, et al. Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias. Cancer Res (2009) 69(9):3986-94. doi:10.1158/0008-5472.CAN-08-3735.
19. Gattazzo C, Teramo A, Miorin M, Scquizzato E, Cabrelle A, Balsamo M, et al. Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes. Haematologica (2010) 95(10):1722-9. doi:10.3324/haematol.2010.023358.
20. Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, et al. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood (2008) 112(12):4694-8. doi:10.1182/blood-2008-02-136382.
21. Scquizzato E, Teramo A, Miorin M, Facco M, Piazza F, Noventa F, et al. Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia (2007) 21(5):1060-9. doi:10.1038/sj.leu.2404634.
22. Zambello R, Trentin L, Ciccone E, Bulian P, Agostini C, Moretta A, et al. Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood (1993) 81(9):2381-5.
23. Epling-Burnette PK, Loughran TP Jr. Survival signals in leukemic large granular lymphocytes. Semin Hematol (2003) 40(3):213-20. doi:10.1016/S0037-1963(03)00135-5.
24. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 99(10):3661-7. doi:10.1182/blood.V99.10.3661.
25. Zambello R, Loughran TP Jr, Trentin L, Pontisso P, Battistella L, Raimondi R, et al. Serologic and molecular evidence for a possible pathogenetic role of viral infection in CD3-negative natural killer-type lymphoproliferative disease of granular lymphocytes. Leukemia (1995) 9(7):1207-11.
26. Thomas A, Perzova R, Abbott L, Benz P, Poiesz MJ, Dube S, et al. LGL leukemia and HTLV. AIDS Res Hum Retroviruses (2010) 26(1):33-40. doi:10.1089/aid.2009.0124.
27. Pellenz M, Zambello R, Semenzato G, Loughran TP Jr. Detection of Epstein-Barr virus by PCR analyses in lymphoproliferative disease of granular lymphocytes. Leuk Lymphoma (1996) 23(3-4):371-4. doi:10.3109/10428199609054841.
28. Zambello R, Loughran TP Jr, Trentin L, Rassu M, Facco M, Bortolin M, et al. Spontaneous resolution of p58/EB6 antigen restricted NK-type lymphoproliferative disease of granular lymphocytes: role of Epstein Barr virus infection. Br J Haematol (1997) 99(1):215-21. doi:10.1046/j.1365-2141.1997.3623176.x.
29. Djaoud Z, David G, Bressollette C, Willem C, Rettman P, Gagne K, et al. Amplified NKG2C+ NK cells in cytomegalovirus (CMV) infection preferentially express killer cell Ig-like receptor 2DL: functional impact in controlling CMV-infected dendritic cells. J Immunol (2013) 191(5):2708-16. doi:10.4049/jimmunol.1301138.
30. Guma M, Budt M, Saez A, Brckalo T, Hengel H, Angulo A, et al. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood (2006) 107(9):3624-31. doi:10.1182/blood-2005-09-3682.
31. Saez-Borderias A, Romo N, Ruiz-Cabello F, Canton J, Tielemans D, Langerak AW, et al. Natural killer cell receptor expression reflects the role of human cytomegalovirus in the pathogenesis of a subset of CD4+ T-cell large granular lymphocytosis. Hum Immunol (2011) 72(3):226-8. doi:10.1016/j.humimm.2010.12.006.
32. Khakoo SI, Carrington M. KIR and disease: a model system or system of models? Immunol Rev (2006) 214:186-201. doi:10.1111/j.1600-065X.2006.00459.x.
33. Beziat V, Liu LL, Malmberg JA, Ivarsson MA, Sohlberg E, Bjorklund AT, et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood (2013) 121(14):2678-88. doi:10.1182/blood-2012-10-459545.
34. Gallez-Hawkins GM, Franck AE, Li X, Thao L, Oki A, Gendzekhadze K, et al. Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection. Biol Blood Marrow Transplant (2011) 17(11):1662-72. doi:10.1016/j.bbmt.2011.04.008.
35. Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C, et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood (2006) 107(3):1230-2. doi:10.1182/blood-2005-03-1039.
36. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet (2002) 31(4):429-34. doi:10.1038/ng934.
37. Pelak K, Need AC, Fellay J, Shianna KV, Feng S, Urban TJ, et al. Copy number variation of KIR genes influences HIV-1 control. PLoS Biol (2011) 9(11):e1001208. doi:10.1371/journal.pbio.1001208.
38. Besson C, Roetynck S, Williams F, Orsi L, Amiel C, Lependeven C, et al. Association of killer cell immunoglobulin-like receptor genes with Hodgkin's lymphoma in a familial study. PLoS One (2007) 2(5):e406. doi:10.1371/journal.pone.0000406.
39. Rivero-Juarez A, Gonzalez R, Camacho A, Manzanares-Martin B, Caruz A, Martinez-Peinado A, et al. Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients. PLoS One (2013) 8(4):e61992. doi:10.1371/journal.pone.0061992.
40. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science (2011) 331(6013):44-9. doi:10.1126/science.1198687.
41. Elliott JM, Yokoyama WM. Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol (2011) 32(8):364-72. doi:10.1016/j.it.2011.06.001.
42. Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol (2006) 6(7):520-31. doi:10.1038/nri1863.
43. Fauriat C, Ivarsson MA, Ljunggren HG, Malmberg KJ, Michaelsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood (2010) 115(6):1166-74. doi:10.1182/blood-2009-09-245746.
44. Orr MT, Murphy WJ, Lanier LL. 'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. Nat Immunol (2010) 11(4):321-7. doi:10.1038/ni.1849.
45. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med (2012) 366(20):1905-13. doi:10.1056/NEJMoa1114885.
46. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood (2012) 120(15):3048-57. doi:10.1182/blood-2012-06-435297.